XNASAPLT
Market cap72mUSD
Jan 17, Last price
0.62USD
1D
0.47%
1Q
-93.04%
IPO
-93.61%
Name
Applied Therapeutics Inc
Chart & Performance
P/E
—
P/S
7.26
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
55.85%
Rev. gr., 5y
%
Revenues
10m
Net income
-120m
L+46.61%
CFO
-55m
L-29.35%
Earnings
Mar 04, 2025
Profile
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
IPO date
May 09, 2019
Employees
22
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 9,993 | ||||||
Cost of revenue | 74,881 | 83,391 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (64,888) | (83,391) | |||||
NOPBT Margin | |||||||
Operating Taxes | (819) | ||||||
Tax Rate | |||||||
NOPAT | (64,888) | (82,572) | |||||
Net income | (119,763) 46.61% | (81,689) -21.91% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 64,514 | 27,811 | |||||
BB yield | -22.86% | -96.74% | |||||
| Debt | |||||||
Debt current | 858 | 477 | |||||
Long-term debt | 505 | 1,305 | |||||
Deferred revenue | |||||||
Other long-term liabilities | 759 | 464 | |||||
Net debt | (48,535) | (28,798) | |||||
| Cash flow | |||||||
Cash from operating activities | (55,173) | (78,093) | |||||
CAPEX | |||||||
Cash from investing activities | 13,872 | 13,170 | |||||
Cash from financing activities | 74,542 | 27,692 | |||||
FCF | (48,342) | (82,129) | |||||
| Balance | |||||||
Cash | 49,898 | 30,580 | |||||
Long term investments | |||||||
Excess cash | 49,398 | 30,580 | |||||
Stockholders' equity | (468,578) | (348,767) | |||||
Invested Capital | 453,087 | 354,183 | |||||
ROIC | |||||||
ROCE | 418.88% | ||||||
| EV | |||||||
Common stock shares outstanding | 84,244 | 37,825 | |||||
Price | 3.35 340.79% | 0.76 -91.51% | |||||
Market cap | 282,219 881.72% | 28,747 -87.45% | |||||
EV | 233,684 | (51) | |||||
EBITDA | (64,534) | (82,948) | |||||
EV/EBITDA | 0.00 | ||||||
Interest | 442 | ||||||
Interest/NOPBT | |||||||